PDSB Stock Price, PDS Biotechnology Corp Quote, Chart

Market Summary

USD3.57-0.21

Delayedas of 08 May 2024, 10:02 am

-5.56%

PDSB Stock Price

View Fullscreen

PDSB RSI Chart

PDSB Valuation

Market Cap

138.6M

Price/Earnings (Trailing)

-3.23

Price/Sales (Trailing)

150.31

EV/EBITDA

-1.65

Price/Free Cashflow

-4.12

PDSB Price/Sales (Trailing)

PDSB Profitability

EBT Margin

-6173.56%

Return on Equity

-164.33%

Return on Assets

-72.31%

Free Cashflow Yield

-24.26%

PDSB Fundamentals

PDSB Revenue

Revenue (TTM)

871.9K

PDSB Earnings

Earnings (TTM)

-42.9M

Breaking Down PDSB Revenue

52 Week Range

3.5710.27

(Low)(High)

Last 7 days

12.8%

Last 30 days

17.0%

Last 90 days

-28.5%

Trailing 12 Months

-43.9%

How does PDSB drawdown profile look like?

PDSB Financial Health

Current Ratio

4.33

PDSB Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2018	851.3K	944.4K	917.6K	871.9K
2017	265.7K	385.3K	543.3K	700.9K
2016	51.8K	99.8K	154.5K	212.3K
2015	0	5.0K	7.0K	9.1K
2014	0	0	3.4K	2.9K
2013	0	0	0	4.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of PDS Biotechnology Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 02, 2022	bedu-addo frank	acquired	1,442,340	6.57	219,535	president/ceo
Dec 02, 2022	bedu-addo frank	sold (taxes)	-1,713,300	9.78	-175,184	president/ceo
Dec 13, 2021	hill matthew c	bought	900	9.00	100	chief financial officer
Dec 13, 2021	hill matthew c	bought	26,060	8.98621	2,900	chief financial officer
Jun 16, 2021	bloomquist delyle w	bought	98,778	9.8778	10,000	-
Jun 16, 2021	bloomquist delyle w	acquired	17,790	5.99	2,970	-
Jun 15, 2021	van voorhees seth	bought	150,000	8.5	17,647	chief financial officer
Jun 15, 2021	glover steve c	bought	49,997	8.5	5,882	-
Jun 15, 2021	freitag gregory gene	bought	49,997	8.5	5,882	-

Which funds bought or sold PDSB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	SG Americas Securities, LLC	sold off	-100	-52,000	-	-%
May 06, 2024	Jefferies Financial Group Inc.	new	-	1,988,000	1,988,000	0.01%
May 03, 2024	GSA CAPITAL PARTNERS LLP	new	-	41,000	41,000	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	new	-	234	234	-%
May 01, 2024	Mirae Asset Global Investments Co., Ltd.	sold off	-100	-256,333	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	added	3.77	-11,715	55,927	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	Avior Wealth Management, LLC	new	-	19.00	19.00	-%
Apr 29, 2024	COMMONWEALTH EQUITY SERVICES, LLC	added	3.7	-67,000	316,000	-%
Apr 25, 2024	Lindbrook Capital, LLC	sold off	-100	-2,485	-	-%

Are Funds Buying or Selling PDSB?

Are funds buying PDSB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PDSB

No. of Funds

Unveiling PDS Biotechnology Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 29, 2024	blackrock inc.	6.0%	1,881,438	SC 13G
Aug 27, 2021	hirschman orin	3.99%	1,135,398	SC 13G/A
Jun 21, 2021	hirschman orin	6.17%	1,750,000	SC 13G
Jun 21, 2021	netscientific plc	4.73%	1,342,670	SC 13D/A
Aug 21, 2020	netscientific plc	5.76%	1,282,670	SC 13D/A
Mar 02, 2020	netscientific plc	7.21%	1,046,670	SC 13D
Feb 21, 2020	peierls e jeffrey	6.95%	1,008,362	SC 13G

Recent SEC filings of PDS Biotechnology Corp

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 02, 2024	3	Insider Trading
Apr 29, 2024	DEFA14A	DEFA14A
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 18, 2024	PRE 14A	PRE 14A
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	10-K	Annual Report
Mar 27, 2024	8-K	Current Report

Peers (Alternatives to PDS Biotechnology Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

PDS Biotechnology Corp News

Latest updates

PDS Biotechnology Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3	2017Q2	2017Q1	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2014Q4	2014Q3	2013Q4
Revenue	-6.1%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Operating Expenses	129.8%	2.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	159.1%	1.00	1.00	0.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	37.5%	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-5.5%	890*	942*	804*	959*	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-155.8%	-1.82	-0.71	-0.57	-0.74	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	3.9%	59.00	57.00	64.00	68.00	77.00	75.00	56.00	61.00	67.00	72.00	77.00	28.00	31.00	34.00	20.00	24.00	14.00	19.00	26.00	31.00	34.00
Current Assets	3.9%	59.00	57.00	63.00	68.00	76.00	74.00	56.00	61.00	67.00	71.00	77.00	27.00	30.00	34.00	19.00	24.00	14.00	18.00	23.00	28.00	0.00
Cash Equivalents	4.2%	57.00	54.00	61.00	65.00	74.00	72.00	53.00	59.00	65.00	70.00	75.00	25.00	29.00	33.00	17.00	21.00	12.00	17.00	22.00	27.00	0.00
Net PPE	-3.4%	0.00	0.00	0.00	0.00	-	-	-	-	86*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	1.7%	33.00	33.00	31.00	27.00	33.00	28.00	5.00	5.00	4.00	4.00	4.00	3.00	4.00	-	-	4.00	3.00	-	-	-	2.00
Current Liabilities	48.9%	14.00	9.00	8.00	4.00	10.00	5.00	5.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	4.00	3.00	4.00	4.00	6.00	2.00
Shareholder's Equity	6.7%	26.00	24.00	32.00	41.00	44.00	47.00	51.00	56.00	63.00	68.00	73.00	24.00	27.00	31.00	17.00	20.00	12.00	16.00	21.00	24.00	30.00
Retained Earnings	-8.2%	-144	-133	-122	-111	-101	-82.42	-75.00	-69.18	-60.70	-54.38	-47.42	-46.83	-43.79	-39.76	-35.85	-32.92	-28.94	-23.83	-18.08	-14.20	-21.94
Additional Paid-In Capital	7.9%	171	158	155	152	146	129	126	125	124	122	120	71.00	71.00	71.00	53.00	53.00	41.00	39.00	39.00	39.00	20.00
Shares Outstanding	6.7%	33.00	31.00	31.00	31.00	30.00	28.00	28.00	26.00	28.00	25.00	23.00	22.00	22.00	-	-	-	-	-	-	-	-
Float	-	-	-	148	-	-	-	98.00	-	-	-	340	-	-	-	23.00	-	-	-	18.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-17.9%	-8,457	-7,175	-4,814	-13,188	-7,528	-5,892	-5,918	-6,369	-4,501	-5,128	946	-3,802	-4,629	-1,252	-4,103	-3,164	-5,519	-4,327	-4,858	-3,367	-317
Share Based Compensation	-34.7%	1,355	2,074	2,106	2,080	1,374	1,344	1,349	1,129	1,673	1,702	442	258	131	130	46.00	125	245	120	19.00	2,755	818
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	275	-	-	29,107	-
Cashflow From Financing	1241.9%	10,766	802	240	4,568	9,707	24,551	22.00	7.00	13*	124	48,766	-	-	17,787	-	12,040	-	-	-	750	279

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PDSB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development expenses	$ 27,762,784	$ 29,431,027
General and administrative expenses	15,282,450	12,241,394
Total operating expenses	43,045,234	41,672,421
Loss from operations	(43,045,234)	(41,672,421)
Interest income (expense), net
Interest income	2,902,939	935,180
Interest expense	(4,205,922)	(1,316,519)
Interest income (expense), net	(1,302,983)	(381,339)
Loss before income taxes	(44,348,217)	(42,053,760)
Benefit from income taxes	1,406,019	1,198,905
Net loss	(42,942,198)	(40,854,855)
Comprehensive loss	$ (42,942,198)	$ (40,854,855)
Per share information:
Net loss per share, basic (in dollars per share)	$ (1.39)	$ (1.43)
Net loss per share, diluted (in dollars per share)	$ (1.39)	$ (1.43)
Weighted average common shares outstanding, basic (in shares)	30,952,060	28,599,221
Weighted average common shares outstanding, diluted (in shares)	30,952,060	28,599,221

PDSB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 56,560,517	$ 73,820,160
Prepaid expenses and other	2,494,558	2,660,230
Total current assets	59,055,075	76,480,390
Property and equipment, net	134,132	0
Financing lease right-to-use assets	200,873	374,888
Operating lease right-to-use asset	0	152,645
Total assets	59,390,080	77,007,923
Current liabilities:
Accounts payable	6,982,824	1,219,287
Accrued expenses	2,424,692	8,313,708
Notes payable - short term	4,166,667	0
Financing lease obligation - short term	55,794	56,612
Operating lease obligation - short term	0	231,429
Total current liabilities	13,629,977	9,821,036
Noncurrent liabilities:
Notes payable, net of debt discount	19,506,183	23,020,844
Financing lease obligation-long term	122,973	164,013
Operating lease obligation-long term	0	0
Total liabilities	33,259,133	33,005,893
STOCKHOLDERS' EQUITY
Common stock, $0.00033 par value, 75,000,000 shares authorized at December 31, 2023 and December 31, 2022, 33,094,521 shares and 30,170,317 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	10,921	9,956
Additional paid-in capital	170,620,641	145,550,491
Accumulated deficit	(144,500,615)	(101,558,417)
Total stockholders' equity	26,130,947	44,002,030
Total liabilities and stockholders' equity	$ 59,390,080	$ 77,007,923

About PDS Biotechnology Corp

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

CEO	Dr. Frank K. Bedu-Addo Ph.D.
WEBSITE	pdsbiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	26

PDS Biotechnology Corp Frequently Asked Questions

What is the ticker symbol for PDS Biotechnology Corp? What does PDSB stand for in stocks?

PDSB is the stock ticker symbol of PDS Biotechnology Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PDS Biotechnology Corp (PDSB)?

As of Tue May 07 2024, market cap of PDS Biotechnology Corp is 138.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PDSB stock?

You can check PDSB's fair value in chart for subscribers.

What is the fair value of PDSB stock?

You can check PDSB's fair value in chart for subscribers. The fair value of PDS Biotechnology Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PDS Biotechnology Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PDSB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PDS Biotechnology Corp a good stock to buy?

The fair value guage provides a quick view whether PDSB is over valued or under valued. Whether PDS Biotechnology Corp is cheap or expensive depends on the assumptions which impact PDS Biotechnology Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PDSB.

What is PDS Biotechnology Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, PDSB's PE ratio (Price to Earnings) is -3.23 and Price to Sales (PS) ratio is 150.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PDSB PE ratio will change depending on the future growth rate expectations of investors.